. zhonghua yi xue za zhi. 2018 ; 98 ( 40 ) : 3274 – 8. references 18. kim hj, fay mp, feuer ej, et al. permutation tests for joinpoint regression with 1. richter t, nestler - parr s, babela r, et al. rare disease terminology and applications to cancer rates [ j ]. stat med. 2000 ; 19 ( 3 ) : 335 – 51. definitions - a systematic global review : report of the ispor rare disease 19. chung cc, wong wh, fung jl, hong kong rd, chung bh. impact of covidspecial interest group. value health. 2015 ; 18 ( 6 ) : 906 – 14. 19 pandemic on patients with rare disease in hong kong. eur j med genet. 2. nguengang wakap s, lambert dm, et al. estimating cumulative point preva - 2020 ; 63 ( 12 ) : 104062. lence of rare diseases : analysis of the orphanet database. eur j hum genet. 20. mazzucato m, visona dalla pozza l, et al. estimating mortality in rare diseases 2020 ; 28 ( 2 ) : 165 – 73. using a population - based registry, 2002 through 2019. orphanet j rare dis. 3. min r, zhang x, fang p, wang b, wang h. health service security of patients 2023 ; 18 ( 1 ) : 362. with 8 certain rare diseases : evidence from china ’ s national system for health 21. x l. descriptive epidemiology investigation and analysis of the rare disease in service utilization of patients with healthcare insurance. orphanet j rare dis. eight provinces, china. master ’ s thesis, pharmacy, jinan university. 2020. 2019 ; 14 ( 1 ) : 204. 22. lu y, gao q, ren x, et al. incidence and prevalence of 121 rare diseases in 4. guo j, liu p, chen l, et al. national rare diseases registry system ( nrdrs ) : china : current status and challenges : 2022 revision. intractable rare dis res. china ’ s first nation - wide rare diseases demographic analyses. orphanet j rare 2022 ; 11 ( 3 ) : 96 – 104. dis. 2021 ; 16 ( 1 ) : 515. 5. aleksovska k, kobulashvili